$IMPL News

Last published 3y ago

3y agoIMPLImpel Pharmaceuticals Announces Exploration of Strategic AlternativesGlobeNewswireSEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people
3y agoIMPLImpel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache SocietyGlobeNewswireReal-World Assessment Suggests that Concomitant Preventive and Acute Medication Use Decreases in Patients Using Trudhesa Additional Poster Underscores the Need for Non-Oral Treatment Options Given the Prevalence of
3y agoIMPLImpel Pharmaceuticals Inc. (IMPL) Q1 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoIMPL CINCImpel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireTrudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call
3y agoIMPLImpel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial OfficerGlobeNewswireSEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with
3y agoIMPLImpel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023GlobeNewswireSEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet
3y agoIMPLImpel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine MedicationsGlobeNewswireNew Analysis Indicates No Drug-Drug Interactions (DDIs) of Clinical Concern are Predicted When Recommended Doses of Trudhesa and Gepants are Co-Administered Additional Analyses from the STOP 301 Trial Show Concomitant
3y agoIMPLImpel Pharmaceuticals Announces Appointment of Darren Cline to the Board of DirectorsGlobeNewswireSEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical
3y agoDNLI EVLO FHTX IMPL+6Cellarity Strengthens Executive Leadership TeamBusiness WireCellarity, a life sciences company founded by Flagship
3y agoIMPLImpel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual MeetingGlobeNewswireSEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical
3y agoIMPLImpel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewswireTrudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to Host Investor
3y agoCDTX ELVN IMPL PEAR+55AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough ScienceGlobeNewswireSAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia
3y agoIMPLImpel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023GlobeNewswireSEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet
3y agoIMPLImpel Pharmaceuticals to Participate in Upcoming Investor Conferences in MarchGlobeNewswireSEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet
3y agoIMPLImpel Pharmaceuticals Announces Strategic Repriortization, Continues Focus on Maximizing Trudhesa® Commercial OpportunityGlobeNewswireCost-Saving Measures Eliminate Pipeline Programs and Reduce Headcount by 16 Percent Company will Continue to Drive Trudhesa Growth Via 90 Field-Based Sales Representatives and Other Commercial Efforts Trudhesa Growth
3y agoIMPLImpel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireTrudhesa® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product Revenue Increased to $3.1 Million Trudhesa surpasses 5% of Acute Branded Prescriptions among prescribers in Q3 One Year After Launch
4y agoIMPLImpel Pharmaceuticals to Participate in Guggenheim 4th Annual Immunology and Neurology DayGlobeNewswireSEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet
4y agoIMPLImpel Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022GlobeNewswireSEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet
4y agoIMPLImpel Pharmaceuticals to Participate in Upcoming Investor Conferences in SeptemberGlobeNewswireSEATTLE, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus
4y agoIMPLImpel Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireTrudhesa® TRx's Grew 48% in Q2 2022 to Over 13K: Net Product Revenue Increased 59% Over Q1 2022 to $2.8 Million Sales Force Expanded by 50% to Capitalize on Prescription Momentum and Market Opportunity Company Reiterated Prescription Guidance Ran
4y agoIMPLImpel Pharmaceuticals to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022GlobeNewswireSEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus o
4y agoIMPLImpel Pharmaceuticals to Participate in 2022 Wedbush PacGrow Healthcare ConferenceGlobeNewswireSEATTLE, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus o
4y agoIMPLImpel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD)GlobeNewswireCALM 201 Study to Explore the Safety and Efficacy of Single 5mg-Dose INP105 Compared to Placebo in Quickly Reducing Agitation in Participants with ASD SEATTLE, July 19, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage
4y agoIMPLImpel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache SocietyGlobeNewswireOral Presentation Showcases Early Ability to Predict Responders to Trudhesa New Analysis Suggest Patient-Reported Benefits of Long-Term Use with Trudhesa Two Additional Analyses Demonstrate Trudhesa Efficacy Regardless of Current Preventive Therap
4y agoIMPLImpel Pharmaceuticals To Present At The JMP Securities Life Sciences ConferenceGlobeNewswireSEATTLE, June 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus o
4y agoIMPLImpel Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireTrudhesa® Continues Strong Launch Trajectory with Q1 2022 TRx Growth of 111% vs. Q4 2021 Planned initiation of INP105 Proof-of-Concept Study for Autism Spectrum Disorder in 2Q 2022 Financing Agreement with Oaktree Capital Extends Cash Runway into
4y agoIMPLImpel Pharmaceuticals to Present at H.C. Wainwright Global Investment ConferenceGlobeNewswireSEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on
4y agoIMPLImpel Pharmaceuticals to Report First Quarter 2022 Financial Results on Monday, May 16, 2022GlobeNewswireSEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus o
4y agoIMPLImpel Neuropharma Announces Company Will Now Be Known as Impel Pharmaceuticals to Reflect Corporate TransformationGlobeNewswireSEATTLE, April 25, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is chan
4y agoIMPLImpel NeuroPharma to Ring Nasdaq Closing Bell on Monday, April 25GlobeNewswireSEATTLE, April 21, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the ce
4y agoIMPLImpel NeuroPharma To Present At The 21st Annual Needham Healthcare ConferenceGlobeNewswireSEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the ce
4y agoIMPLImpel NeuroPharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswireTrudhesa™ Exceeds Fourth Quarter 2021 Prescription Guidance; Strong Launch Continues Into 2022 Demonstrated by 157% Growth Since December 31, 2021 Planned Initiation of INP105 Proof-Of-Concept Study for Autism Spectrum Disorder in First Half of 2022
4y agoIMPLImpel NeuroPharma to Present Trudhesa™ Data at 2022 Scientific Meeting of American Academy of NeurologyGlobeNewswireNew Data Suggests Rapid, Sustained, and Consistent Migraine Relief with Trudhesa Treatment New Analysis Considers Efficacy of Trudhesa After Variety of Acute Therapies Post Hoc Pivotal Trial Data Indicates that Trudhesa Use Was Associated with Redu
4y agoIMPLImpel NeuroPharma to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022GlobeNewswireSEATTLE, March 17, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the ce
4y agoIMPLImpel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With OaktreeGlobeNewswire-Transaction Provides Immediate, Non-Dilutive Capital to Further Support Commercialization of Trudhesa™ -$100 million in gross proceeds to be funded at close, extending estimated corporate cash runway into 2024 SEATTLE, March 17, 2022 (GLOBE N
4y agoIMPLImpel NeuroPharma to Participate in Upcoming Virtual Investor ConferencesGlobeNewswireSEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the cen
4y agoIMPLImpel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business HighlightsGlobeNewswireTrudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company's Guidance Range Achieved Broad and Favorable Trudhesa™ Payer Coverage with Signed Agreements
4y agoIMPLImpel NeuroPharma Announces Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireLaunched Trudhesa™ (dihydroergotamine mesylate) Nasal Spray (0.725 mg per spray) for the Acute Treatment of Migraine with and without Aura in Adults Mobilized 60-Person Salesforce with a Targeted Focus on High-Prescribing Neurologists, Headache Spec
5y agoIMPLImpel NeuroPharma to Present at the Guggenheim Securities 3rd Annual Neuro/Immunology ConferenceGlobeNewswireSEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus o
5y agoIMPLImpel NeuroPharma to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021GlobeNewswireSEATTLE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus o
5y agoIMPLPhil Announces Partnership with Impel NeuroPharma in Support of Trudhesa™ (dihydroergotamine mesylate) Nasal Spray for the Acute Treatment of MigrainePR NewswireSAN FRANCISCO, Sept. 29, 2021 /PRNewswire/ -- Phil, Inc. announces partnership with Impel NeuroPharma, Inc. (NASDAQ: IMPL) in support of Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) to provide technology-powered patient
5y agoIMPLCarepoint Pharmacy Selected by Impel NeuroPharma as a Digital Pharmacy Partner for the Launch of Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of MigrainePR NewswireSCHAUMBURG, Ill., Sept. 28, 2021 /PRNewswire/ -- Carepoint Pharmacy announces that it will partner with Impel NeuroPharma, Inc. (NASDAQ: IMPL) to begin dispensing Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the ac
5y agoIMPLImpel NeuroPharma Announces Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for the Acute Treatment of MigraineGlobeNewswireTrudhesa is the First and Only Therapeutic to Use POD® Technology to Deliver Dihydroergotamine Mesylate (DHE)—a Proven, Well-Established Therapeutic—to the Vascular-Rich Upper Nasal Space Trudhesa is Available Through Trudhesa Direct™
5y agoIMPLImpel NeuroPharma Announces Pricing of $45.0 Million Public OfferingGlobeNewswireSEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus
5y agoIMPLImpel NeuroPharma Announces Launch of Proposed Public OfferingGlobeNewswireSEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus
5y agoIMPLImpel NeuroPharma Announces U.S. FDA Approval of TRUDHESA™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of MigraineGlobeNewswireTRUDHESA Is the First and Only Therapeutic to Use POD technology to Deliver Dihydroergotamine Mesylate (DHE) to the Vascular-Rich Upper Nasal Space TRUDHESA Is Well Tolerated and Delivers Rapid, Sustained and Consistent Symptom Relief for the Acute Tr
5y agoIMPLImpel NeuroPharma Announces Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireTRUDHESA™ New Drug Application (NDA) Under Review by U.S. Food & Drug Administration (FDA) with PDUFA Target Action Date of September 6, 2021 Preparations On Track for Potential TRUDHESA Launch in the Fourth Quarter of 2021 Increased Cash Po
5y agoIMPLImpel NeuroPharma to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021GlobeNewswireSEATTLE, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ:IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS)
5y agoIMPLImpel NeuroPharma Announces Publication of Pivotal Phase 3, Open-Label Stop 301 Study of INP104 (TRUDHESA™) for Treatment of Acute Migraine in the Journal HeadacheGlobeNewswireStudy Shows TRUDHESA™ Was Well Tolerated and Delivered Rapid, Consistent Symptom Relief Exploratory Patient-Reported Outcomes Data Indicated More Than One Third of Patients Experienced Pain Freedom and Two Thirds Had Pain Relief Two Hours Following
5y agoIMPLImpel NeuroPharma to Present at the 2021 Wedbush Pacgrow Virtual Healthcare ConferenceGlobeNewswireSEATTLE, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ:IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS)